Safie Inc.
Notice Regarding Recording of Extraordinary Loss
For the fiscal year ending December 2025, an impairment loss of 176 million JPY on investment securities and 303 million JPY on affiliated company shares were recorded as extraordinary losses.
Key Figures
- Impairment Loss on Investment Securities: 176 million JPY (Extraordinary loss due to impairment processing)
- Impairment Loss on Affiliated Company Shares: 303 million JPY (Impairment of shares of consolidated subsidiaries and affiliated companies)
- Equity-Method Investment Loss: 19 million JPY (Impairment loss on affiliated company shares)
AI要約
Details of the Recorded Extraordinary Loss
During the full fiscal year ending December 2025, impairment processing was conducted on investment securities held by our consolidated subsidiaries whose fair value declined significantly, resulting in the recording of an "Impairment Loss on Investment Securities" of 176 million JPY as an extraordinary loss. Additionally, impairment processing was performed on shares of one consolidated subsidiary and one affiliated company after examining future recoverability, which led to recording an "Impairment Loss on Affiliated Company Shares" of 303 million JPY. The impairment loss on affiliated company shares is recorded as a 19 million JPY equity-method investment loss.
Impact on Performance
These extraordinary losses are already reflected in the consolidated financial summary [Japanese GAAP] for the fiscal year ending December 2025 and have negatively impacted the results for that period. Although specific figures for sales and profits are not provided in this document, it is presumed that the recording of extraordinary losses has affected net income and other metrics.
